Press Release: atai Life Sciences launches TryptageniX to further expand atai’s intellectual property portfolio and strengthen atai’s supply chain
Cannabis Law Report
DECEMBER 9, 2021
Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the launch of TryptageniX. We both share a strong commitment to driving novel approaches in the treatment of mental health disorders. NEW YORK, Dec. References: Rehm J, Shield KD.
Let's personalize your content